<DOC>
	<DOCNO>NCT01283971</DOCNO>
	<brief_summary>This randomize , parallel-group study ass efficacy safety RoActemra/Actemra ( tocilizumab ) versus adalimumab , combination methotrexate ( MTX ) patient moderate severe active rheumatoid arthritis . Patients , already treat MTX stable dos , randomize receive either RoActemra/Actemra 8 mg/kg intravenously ( IV ) every 4 week adalimumab 40 mg subcutaneous ( SC ) every 2 week . All patient receive methotrexate ( 10-25 mg weekly ) folate ( least 5 mg weekly ) . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study RoActemra/Actemra ( Tocilizumab ) Versus Adalimumab Combination With Methotrexate ( MTX ) Patients With Moderate Severe Active Rheumatoid Arthritis And Inadequate Response Treatment With Only One Tumor Necrosis Factor ( TNF ) -Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Rheumatoid arthritis &gt; /= 6 month duration ( accord American College Rheumatology ( ACR ) criterion ) ( accord ACR criterion ) Inadequate response due inefficacy treatment ( least 3 month ) one approve Tumor Necrosis Factor ( TNF ) agent adalimumab Depending TNFinhibitor , last dose TNFinhibitor 1 8 week randomization study On methotrexate treatment &gt; /=12 week immediately prior baseline , stable dose ( 1025 mg/week ) last 8 week Disease Activity Score ( DAS28 ) &gt; 3.2 baseline Oral corticosteroid ( &lt; /=10 mg/day prednisone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ) permit dose stable &gt; /=6 week prior baseline . Major surgery ( include joint surgery ) within 8 week prior screen plan surgery within 6 month follow randomization Rheumatic autoimmune disease rheumatoid arthritis Prior history current inflammatory joint disease rheumatoid arthritis Functional class IV ( ACR criterion ) History severe allergic reaction human , humanize murine monoclonal antibody Known active current history recurrent infection ( include tuberculosis ) Primary secondary immunodeficiency ( history currently active ) Body weight &gt; 150 kg Previous treatment celldepleting therapy Previous treatment tocilizumab Intraarticular parenteral corticosteroid within 6 week prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>